Menu

Image of the Day: Release Your Inhibitions

A drug commonly used to treat clinical depression sets its effects in motion by hampering the release of an inhibitory neurotransmitter in mice.

Jul 31, 2017
The Scientist Staff

In the mouse dentate gyrus, cholecystokinin neurons (red) and a protein they produce (p11; green) that's critical for initiating a response to selective serotonin reuptake inhibitors LABORATORY OF MOLECULAR AND CELLULAR NEUROSCIENCE AT THE ROCKEFELLER UNIVERSITY/NEURON Selective serotonin reuptake inhibitors (SSRIs) are drugs used to manage depressive disorders, but their precise mode of action is elusive. Researchers recently demonstrated that SSRIs target certain receptors on cholecystokinin neurons in the mouse hippocampus and prevent them from releasing inhibitory neurotransmitters, the first steps in a longer cascade.

See L. Medrihan et al., “Initiation of Behavioral Response to Antidepressants by Cholecystokinin Neurons of the Dentate Gyrus,” Neuron, 95:1-13, 2017.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.